Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Metadata referenced "Biolife Solutions," but the filing text identifies the registrant as Cryomedical Sciences, Inc.)
Reporting Period: Quarterly period ended March 31, 1996 (Nine months ended March 31, 1996 for comparative data).
Business Overview: The Company researches, develops, manufactures, and markets products for hypothermic medicine, primarily the CMS AccuProbe(R) cryosurgical system used in urology, general surgery, and other fields.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1996 | Nine Months Ended Mar 31, 1996 | Nine Months Ended Mar 31, 1995 |
|---|---|---|---|
| Sales & Other Revenues | $2,026,593 | $5,708,743 | $10,921,890 |
| Gross Profit | $1,012,490 | $3,054,964 | $5,879,271 |
| Gross Margin | 50% | 54% | 54% |
| Net Loss | $(412,668) | $(1,416,165) | $(1,418,096) |
| Net Loss Per Share | $(0.02) | $(0.06) | $(0.06) |
| Cash & Equivalents (End of Period) | $1,265,757 (as of Mar 31, 1996) | ||
| Working Capital | |||
| Total Liabilities | $2,524,812 (as of Mar 31, 1996) |
Cash Flow (Nine Months Ended Mar 31, 1996):
- Net cash used in operating activities: $(1,782,574)
- Net cash used in investing activities: $(56,252)
- Net cash provided by financing activities: $1,987,200 (primarily from $1.91M in stock proceeds)
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 33% for the quarter and 48% for the nine-month period compared to the prior year. This was driven by a drop in AccuProbe system sales (7 systems sold in Q4 1996 vs. 9 in Q4 1995; 16 systems in 9 months 1996 vs. 33 in 9 months 1995).
- Ultrasound Revenue: Revenue from third-party ultrasound systems dropped to zero in the current period, compared to $732,188 in the prior nine-month period.
- Expense Reductions: Operating expenses decreased significantly due to cost-cutting measures:
- Research & Development: Down 54% (quarter) and 55% (nine months).
- Sales & Marketing: Down 41% (quarter) and 34% (nine months).
- General & Administrative: Down 32% (quarter) and 28% (nine months).
- Net Loss: Despite lower revenues, the net loss for the nine months ended March 31, 1996, was slightly lower than the prior year ($1.416M vs. $1.418M) due to aggressive expense management.
Guidance, Outlook, Risks, and Contingencies
- Reimbursement Risk: The primary driver of revenue decline is the lack of formal Medicare reimbursement for urologic cryosurgery. Medicare currently considers the procedure investigational. The Company notes that widespread formal reimbursement acceptance has not yet been achieved, impacting sales growth.
- Liquidity: The Company raised $1.91 million in net proceeds from a convertible preferred stock sale to foreign investors in January 1996. Management believes current cash and working capital ($4.1M) are sufficient to fund operations for the next 12 months, contingent on sales levels.
- Legal Contingencies:
- Class Action Settlement: A shareholder class action suit was settled for $100,000 cash and 175,549 shares of common stock (valued at $350,000). The total cost was accrued as of June 30, 1995. The cash portion was paid, and shares were issued in February 1996.
- Employment Suit: A gender bias lawsuit filed by a former employee was dismissed with prejudice; no payment is required.
- Management Changes: On May 7, 1996, President and CEO J. J. Finkelstein resigned. John G. Baust, Ph.D., is serving as Acting Chief Operating Officer.
Investor Verification Checklist
- Verify the status of Medicare and private insurer reimbursement guidelines for urologic cryosurgery, as this is the critical bottleneck for revenue recovery.
- Confirm the conversion status of the $1.91M convertible preferred stock issued to foreign investors and any subsequent dilution.
- Monitor the timeline for the appointment of a permanent CEO following the resignation of J. J. Finkelstein.
- Review the Company's ability to sustain operations without further equity financing if sales do not rebound in the next 12 months.
- Check for any new legal filings or updates regarding the class action settlement distribution process.